Treatment with geraniol ameliorates methionine‐choline‐deficient diet‐induced non‐alcoholic steatohepatitis in rats

Fan, Xiaoxia; Zhou, Lin; Gao, Xiaogang

doi:10.1111/jgh.13272

Cited by 26 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mild down-regulation exerted by geraniol on phase I enzymes (CYP3A1/2, CYP2E1, CYP1A2) might be of particular interest in pathological conditions as confirmed by Chen and coworkers ( Chen et al, 2016 ) and Madankumar et al (2013) . In particular, Chen and coworkers showed how geraniol was able to ameliorate non-alcoholic steatohepatitis (NASH) induced by methionine-choline-deficient (MCD) diet in rats, also via CYP2E1 inactivation.…”

Section: Discussionmentioning

confidence: 72%

Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes

et al. 2018

View full text Add to dashboard Cite

Geraniol is a natural monoterpene showing anti-inflammatory, antioxidant, neuroprotective and anticancer effects. No pharmacokinetic and bioavailability data on geraniol are currently available. We therefore performed a systematic study to identify the permeation properties of geraniol across intestinal cells, and its pharmacokinetics and bioavailability after intravenous and oral administration to rats. In addition, we systematically investigated the potential hepatotoxic effects of high doses of geraniol on hepatic phase I, phase II and antioxidant enzymatic activities and undertook a hematochemical analysis on mice. Permeation studies performed via HPLC evidenced geraniol permeability coefficients across an in vitro model of the human intestinal wall for apical to basolateral and basolateral to apical transport of 13.10 ± 2.3 × 10-3 and 2.1 ± 0.1⋅× 10-3 cm/min, respectively. After intravenous administration of geraniol to rats (50 mg/kg), its concentration in whole blood (detected via HPLC) decreased following an apparent pseudo-first order kinetics with a half-life of 12.5 ± 1.5 min. The absolute bioavailability values of oral formulations (50 mg/kg) of emulsified geraniol or fiber-adsorbed geraniol were 92 and 16%, respectively. Following emulsified oral administration, geraniol amounts in the cerebrospinal fluid of rats ranged between 0.72 ± 0.08 μg/mL and 2.6 ± 0.2 μg/mL within 60 min. Mice treated with 120 mg/kg of geraniol for 4 weeks showed increased anti-oxidative defenses with no signs of liver toxicity. CYP450 enzyme activities appeared only slightly affected by the high dosage of geraniol.

show abstract

Section: Discussionmentioning

confidence: 72%

Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Geraniol was demonstrated to possess numerous pharmacological actions, including neuroprotective [ 13 ], antioxidant [ 13 ], antinociceptive [ 14 ], anti-inflammatory, antifungal [ 15 ], anti-arrhythmic [ 12 ], anti-osteoarthritis [ 9 ], and antitumor [ 16 ] activities. In addition, geraniol is a promising drug candidate for diverse health problems such as ulcerative colitis [ 17 ], non-alcoholic steatohepatitis [ 18 ], hyperlipidemia [ 19 ], cardiac complications of diabetes [ 10 ], and neuropathic pain [ 20 ]. Clinically, dietary geraniol might be an influential constituent as a food supplement for irritable bowel syndrome (IBS) via ameliorating intestinal dysbiosis and relieving IBS symptoms [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Protective Effect of Geraniol on Oxidative, Inflammatory and Apoptotic Alterations in Isoproterenol-Induced Cardiotoxicity: Role of the Keap1/Nrf2/HO-1 and PI3K/Akt/mTOR Pathways

2020

View full text Add to dashboard Cite

Background: Myocardial infarction (MI) is still a major contributor to mortality worldwide, and therefore, searching for new drugs is an urgent priority. Natural products are a renewable source for medicinally and pharmacologically active molecules. The objective of this study was to explore the potential of geraniol, a monoterpene alcohol, to protect against MI. Methods: Five groups of Wister rats were used: a control group; a group treated only with geraniol; a group treated only with isoproterenol, to induce MI; and two groups pretreated with geraniol (100 or 200 mg/kg, respectively) for 14 days and challenged with isoproterenol on the 13th and 14th days. Several parameters were measured including electrocardiogram (ECG), cardiac markers, the expression of Kelch-like ECH-associated protein 1 (Keap1), nuclear factor erythroid 2-related factor 2 (Nrf2), and other downstream antioxidant enzymes, as well as the expression of phosphoinositide 3-kinases (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and other downstream apoptotic and inflammatory mediators. Results: Geraniol treatment reduced the size of the infarct region, attenuated the levels of cardiac indicators, and diminished myocardial necrosis and immune cell infiltration. Geraniol treatment also activated the Keap1/Nrf2/heme oxygenase-1 (HO-1) pathway, increased antioxidant enzyme activities, modulated the PI3K/Akt/mTOR pathway, and ameliorated myocardial autophagy, inflammation, and apoptosis. Conclusion: Geraniol may possess a protective effect against MI through moderating MI-induced myocardial oxidative stress (glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione S-transferase (GST), and Keap1/Nrf2 pathway), inflammation (IL-1β, IL-6, TNF-α, and Nuclear factor-κB (NF-κB)), apoptosis (caspase-3, caspase-9, Bcl2, and Bax), and autophagy (PI3K/Akt/mTOR pathway).

show abstract

“…Geraniol is an acyclic monoterpene alcohol found in medicinal plants and used traditionally for several medical purposes including diabetes [55]. Geraniol possesses pharmacological effects such as anti-oxidant, anticancer and anti-inflammatory properties [56,57,58]. Under the present experimental conditions, geraniol per se did not affect body weight gain, plasma glucose, TGA or insulin levels.…”

Section: Accepted Manuscriptmentioning

confidence: 61%

Reversion of down-regulation of intestinal multidrug resistance-associated protein 2 in fructose-fed rats by geraniol and vitamin C: Potential role of inflammatory response and oxidative stress

Zecchinati

Barranco

Arana

et al. 2019

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

show abstract

Treatment with geraniol ameliorates methionine‐choline‐deficient diet‐induced non‐alcoholic steatohepatitis in rats

Abstract: Treatment with geraniol attenuated MCD-induced NASH in rats.

Cited by 26 publications

References 48 publications

Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes

Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes

Protective Effect of Geraniol on Oxidative, Inflammatory and Apoptotic Alterations in Isoproterenol-Induced Cardiotoxicity: Role of the Keap1/Nrf2/HO-1 and PI3K/Akt/mTOR Pathways

Reversion of down-regulation of intestinal multidrug resistance-associated protein 2 in fructose-fed rats by geraniol and vitamin C: Potential role of inflammatory response and oxidative stress

Contact Info

Product

Resources

About